Alembic Pharma Q4 Review - U.S. Continues To Be Under Pressure: ICICI Securities
An employee scoops up tablet cores for inspection at a pharmaceutical plant in Germany. (Photographer: Hannelore Foerster/Bloomberg)

Alembic Pharma Q4 Review - U.S. Continues To Be Under Pressure: ICICI Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

Alembic Pharmaceuticals Ltd. reported Q4 FY21 performance largely in line with estimates, though Ebitda margin was higher due to lower operating costs.

Revenue in U.S. was below expectation at ~$63 million due to competitive pressure in sartans and the management indicated the U.S. revenue quarterly base would be between $55-60 million.

Consolidated revenues grew 6.1% YoY to Rs 12.8 billion (our estimate: Rs 13.1 billion), adjusted profit grew 7.6% YoY to Rs 2.5 billion (our estimate: Rs 2.0 billion) and Ebitda margin dropped 40 basis points YoY to 26.7% (our estimate: 24.7%).

Click on the attachment to read the full report:

ICICI Securities Alembic Q4FY21 Results Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.